Lancet data support Amgen's PCSK9 inhibitor as race hots up
This article was originally published in Scrip
Executive Summary
As the race to be first to market with a PCSK9 inhibitor reaches its final, tense stages, one competitor, Amgen, has published the results of two of its pivotal trials for its offering evolocumab in The Lancet.